IMATINIB Drug Patent Profile
✉ Email this page to a colleague
When do Imatinib patents expire, and what generic alternatives are available?
Imatinib is a drug marketed by Amneal Pharms, Apotex, Chartwell Rx, Cspc Ouyi, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Hikma, Mylan, Natco Pharma Ltd, Novitium Pharma, Qilu Pharm Hainan, Shilpa, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in sixteen NDAs.
The generic ingredient in IMATINIB is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Imatinib
A generic version of IMATINIB was approved as imatinib mesylate by TEVA PHARMS USA on August 4th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IMATINIB?
- What are the global sales for IMATINIB?
- What is Average Wholesale Price for IMATINIB?
Summary for IMATINIB
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 16 |
| Drug Prices: | Drug price information for IMATINIB |
| DailyMed Link: | IMATINIB at DailyMed |
US Patents and Regulatory Information for IMATINIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 210658-002 | Apr 8, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 078340-002 | Dec 3, 2015 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 204285-001 | Aug 4, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal Pharms | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 207495-001 | Feb 8, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
